Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2025
Event: Entry into a Material Definitive Agreement involving the inducement exercise of existing warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.6 million expected from the exercise of existing warrants.
- Shares Issued: 6,595,000 shares of common stock issued upon exercise of Existing Warrants (Series A, B-1, C-1, D, E, and F).
- Exercise Price: Reduced to $0.70 per share for the Existing Warrants.
- New Securities: Issuance of unregistered New Series H Warrants to purchase up to 6,595,000 shares of common stock.
- New Warrant Terms: Exercise price of $0.70 per share; exercisable after 6 months; term of 66 months.
- Transaction Costs: Placement agent (Ladenburg Thalmann & Co., Inc.) fee of 8.0% of gross proceeds plus a 1.0% management fee and reimbursement of legal expenses.
- Use of Proceeds: General corporate purposes.
Material Changes and Transaction Structure
The Company entered into an Inducement Letter with 7 holders of existing warrants. In consideration for the immediate cash exercise of these warrants at a reduced price, the Company agreed to issue new Series H warrants. This transaction represents a material change in the Company's capital structure and liquidity position, increasing cash on hand while simultaneously increasing the potential future share count through the new warrants.
Guidance, Outlook, and Restrictions
- Closing Date: Expected on July 10, 2025, subject to customary conditions.
- Registration Obligations: The Company must file a Form S-1 Resale Registration Statement within 15 days of closing and use best efforts to have it declared effective within 45 days (or 75 days if reviewed).
- Lock-up/Restrictions:
- 15-day moratorium on issuing new common stock or equivalents (with exceptions for employee compensation plans).
- 6-month moratorium on entering into variable rate financing.
- Management Commentary: The filing does not provide specific operational guidance or clinical trial updates beyond the transaction details.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting the 9% total placement agent fees and expenses.
- Confirm the effective date of the Form S-1 Resale Registration Statement for the New Series H Warrants.
- Review the full text of the Inducement Letter (Exhibit 10.1) for specific representations, warranties, and any additional covenants not summarized here.
- Assess the dilution impact of the 6,595,000 new shares issued immediately and the potential 6,595,000 shares underlying the New Series H Warrants.
- Monitor the Company's cash burn rate to determine how long the $4.6 million in gross proceeds will sustain operations.